Note 8 - Accounts Receivable |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts and Nontrade Receivable [Text Block] |
Note 8. Accounts Receivable
At December 31, 2023 and 2022, accounts receivable consisted of the following (in thousands):
Bad debt expense was approximately $47,000 and $0 for the twelve months ended December 31, 2023 and 2022, respectively.
The increase in accounts receivable was attributable to the consolidation of Progressive Care at July 1, 2023. |
X | ||||||||||
- Definition The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Details
|